Micro-clotting has emerged as a critical concern, especially following COVID-19 and related vaccinations. In this lecture, Dr. Jordan Vaughn, CEO and Owner of MedHelp Clinics, addresses this challenge head-on. Drawing from his family’s medical legacy, Dr. Vaughn has made significant strides in identifying and treating micro-clotting, which is distinct from traditional clotting disorders. He presents innovative treatments tailored for spike-protein-related conditions. Dr. Vaughn’s insights emphasize the importance of recognizing and managing microvascular damage, offering hope through advanced medical strategies.
This is Michael Ferres , a G.P. in Australia, a newcomer to this information about treating the consequences of spike protein exposure. I can see the value of treating microclots. When patients have had angioplasties or stents for coronary disease they are usually treated postoperatively for some months with aspirin and a platelet agent, but not anticoagulation. Is there any risk with triple therapy of aspirin and clopidogrel and DOAC, especially if nattokinase is also used?
Thank you for posting, I shared it with the team at IMA.